Recent progress in structure-based anti-influenza drug design

Drug Discovery Today

Volumn 17, Issue 19-20, 2012, Pages 1111-1120

  Du, Juan ^a,b   Cross, Timothy A ^b,c   Zhou, Huan Xiang ^a,b  

^a Florida State University   (United States)

^b FLORIDA STATE UNIVERSITY   (United States)

^c FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A315675; AMANTADINE; ANTIVIRUS AGENT; BL1743; HEMAGGLUTININ; INFLUENZA VACCINE; NUCLEOPROTEIN; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; RNA POLYMERASE; SIALIDASE; UNCLASSIFIED DRUG; ZANAMIVIR;

DRUG DESIGN; DRUG POTENCY; DRUG RESISTANCE; DRUG STRUCTURE; HUMAN; IC 50; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PROTEIN BINDING; REVIEW;

ANTIVIRAL AGENTS; DRUG DESIGN; HUMANS; INFLUENZA, HUMAN; MOLECULAR STRUCTURE; VIRAL PROTEINS;

EID: 84866740262     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.06.002     Document Type: Review

References (116)

1. World Health Organization Website. http://www.who.int/
2. N.J. Cox, and K. Subbarao Global epidemiology of influenza: past and present Annu. Rev. Med. 51 2000 407 421
3. L.V. Gubareva Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir J. Infect. Dis. 183 2001 523 531
4. L. Gubareva Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009 Morb. Mortal. Wkly. Rep. 58 2009 433 435
5. P. Palese, and J.F. Young Variation of influenza A, B, and C viruses Science 215 1982 1468 1474
6. E. Ghedin Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution Nature 437 2005 1162 1166
7. W. Chen A novel influenza A virus mitochondrial protein that induces cell death Nat. Med. 7 2001 1306 1312
8. V.P. Mishin Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors Antimicrob. Agents Chemother. 49 2005 4515 4520
9. A. Meijer Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season Emerg. Infect. Dis. 15 2009 552 560
10. R.A. Bright Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States J. Am. Med. Assoc. 295 2006 891 894
11. V.M. Deyde Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide J. Infect. Dis. 196 2007 249 257
12. Y. Furuse Large-scale sequence analysis of M gene of influenza A viruses from different species: mechanisms for emergence and spread of amantadine resistance Antimicrob. Agents Chemother. 53 2009 4457 4463
13. R.M. Krug, and J.M. Aramini Emerging antiviral targets for influenza A virus Trends Pharmacol. Sci. 30 2009 269 277
14. K. Das Structures of influenza A proteins and insights into antiviral drug targets Nat. Struct. Mol. Biol. 17 2010 530 538
15. J.J. Skehel, and D.C. Wiley Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin Annu. Rev. Biochem. 69 2000 531 569
16. S.C. Harrison Viral membrane fusion Nat. Struct. Mol. Biol. 15 2008 690 698
17. E. Nobusawa Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses Virology 182 1991 475 485
18. Y. Ha X-ray structures of H5 avian and H9 swine influenza virus hemagglutinins bound to avian and human receptor analogs Proc. Natl. Acad. Sci. U. S. A. 98 2001 11181 11186
19. S.J. Gamblin The structure and receptor binding properties of the 1918 influenza hemagglutinin Science 303 2004 1838 1842
20. J. Stevens Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus Science 312 2006 404 410
21. H. Yang Structures of receptor complexes of a North American H7N2 influenza hemagglutinin with a loop deletion in the receptor binding site PLoS Pathog. 6 2010 e1001081
22. 1) Bioinformation 2 2008 240 244
23. D.L. Bodian Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones Biochemistry 32 1993 2967 2978
24. K.A. Staschke Inhibition of influenza virus hemagglutinin-mediated membrane fusion by a compound related to podocarpic acid Virology 248 1998 264 274
25. M.S. Deshpande An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology Bioorg. Med. Chem. Lett. 11 2001 2393 2396
26. R.J. Russell Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion Proc. Natl Acad. Sci. U. S. A. 105 2008 17736 17741
27. G. Tang Discovery of novel 1-phenyl-cycloalkane carbamides as potent and selective influenza fusion inhibitors Bioorg. Med. Chem. Lett. 20 2010 3507 3510
28. D.C. Ekiert Antibody recognition of a highly conserved influenza virus epitope Science 324 2009 246 251
29. J. Sui Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses Nat. Struct. Mol. Biol. 16 2009 265 273
30. D. Corti A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins Science 333 2011 850 856
31. S.J. Fleishman Computational design of proteins targeting the conserved stem region of influenza hemagglutinin Science 332 2011 816 821
32. P. Palese, and R.W. Compans Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action J. Gen. Virol. 33 1976 159 163
33. H.D. Klenk, and R. Rott The molecular biology of influenza virus pathogenicity Adv. Virus Res. 34 1988 247 281
34. R.J. Russell The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design Nature 443 2006 45 49
35. J.N. Varghese The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor Proteins 14 1992 327 332
36. C.L. White A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies J. Mol. Biol. 245 1995 623 634
37. M. von Itzstein Rational design of potent sialidase-based inhibitors of influenza virus replication Nature 363 1993 418 423
38. C.U. Kim Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity J. Am. Chem. Soc. 119 1997 681 690
39. M. von Itzstein The war against influenza: discovery and development of sialidase inhibitors Nat. Rev. Drug Discov. 6 2007 967 974
40. Y.S. Babu BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design J. Med. Chem. 43 2000 3482 3486
41. W.M. Kati In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication Antimicrob. Agents Chemother. 46 2002 1014 1021
42. K.G. Watson Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase Bioorg. Med. Chem. Lett. 14 2004 1589 1592
43. H.L. Yen Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility Antimicrob. Agents Chemother. 49 2005 4075 4084
44. R.E. Amaro Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design J. Am. Chem. Soc. 129 2007 7764 7765
45. R.E. Amaro Mechanism of 150-cavity formation in influenza neuraminidase Nat. Commun. 2 2011 388
46. A.T. García-Sosa Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant J. Chem. Inf. Model. 48 2008 2074 2080
47. L.S. Cheng Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase J. Med. Chem. 51 2008 3878 3894
48. Y. Li Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1 J. Mol. Graph. Model. 28 2009 203 219
49. P.M. Mitrasinovic On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA) Biophys. Chem. 140 2009 35 38
50. W-H. Wen Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses Bioorg. Med. Chem. 18 2010 4074 4084
51. S. Rudrawar Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase Nat. Commun. 1 2010 113
52. J. An A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase J. Med. Chem. 52 2009 2667 2672
53. T. Rungrotmongkol Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1 Antivir. Res. 82 2009 51 58
54. J.W. Park, and W.H. Jo Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus Eur. J. Med. Chem. 45 2010 536 541
55. S-Q. Wang Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus Biochem. Biophys. Res. Commun. 401 2010 188 191
56. J.D. Durrant, and J.A. McCammon Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design Comput. Biol. Chem. 34 2010 97 105
57. T. Rungrotmongkol Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance Comb. Chem. High Throughput Screen. 13 2010 268 277
58. M.K. Gilson, and H.X. Zhou Calculation of protein-ligand binding affinities Annu. Rev. Biophys. Biomol. Struct. 36 2007 21 42
59. M. Sharma Insight into the mechanism of the influenza A proton channel from a structure in a lipid bilayer Science 330 2010 509 512
60. J.S. Rossman, and R.A. Lamb Influenza virus assembly and budding Virology 411 2011 229 236
61. B.J. Chen The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding J. Virol. 82 2008 10059 10070
62. J.R. Schnell, and J.J. Chou Structure and mechanism of the M2 proton channel of influenza A virus Nature 451 2008 591 595
63. A.L. Stouffer Structural basis for the function and inhibition of an influenza virus proton channel Nature 451 2008 596 599
64. J. Hu Backbone structure of the amantadine-blocked trans-membrane domain M2 proton channel from influenza A virus Biophys. J. 92 2007 4335 4343
65. M. Yi A secondary gate as a mechanism for inhibition of the M2 proton channel by amantadine J. Phys. Chem. B 112 2008 7977 7979
66. S.D. Cady Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers Nature 463 2010 689 692
67. T.A. Cross M2 protein from influenza A: from multiple structures to biophysical and functional insights Curr. Opin. Virol. 2 2012 128 133
68. V. Prelog, and R. Seiwerth Über eine neue, ergiebigere Darstellung des Adamantans Ber. Dtsch. Chem. Ges. A/B 74 1941 1769 1772
69. S. Kurtz Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of influenza virus Antimicrob. Agents Chemother. 39 1995 2204 2209
70. R.A. Bright High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season Morb. Mortal. Wkly. Rep. 55 2006 44 46
71. W. Hu Identification of hits as Matrix-2 protein inhibitors through the focused screening of a small primary amine library J. Med. Chem. 53 2010 3831 3834
72. X. Zhao Discovery of highly potent agents against influenza A virus Eur. J. Med. Chem. 46 2011 52 57
73. J. Wang Exploring the requirements for the hydrophobic scaffold and polar amine in inhibitors of M2 from influenza A virus ACS Med. Chem. Lett. 2 2011 307 312
74. M.D. Duque Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus J. Med. Chem. 54 2011 2646 2657
75. J. Wang Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus J. Am. Chem. Soc. 131 2009 8066 8076
76. V. Balannik Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus Biochemistry 48 2009 11872 11882
77. J. Wang Molecular dynamics simulation directed rational design of inhibitors targeting drug-resistant mutants of influenza A virus M2 J. Am. Chem. Soc. 133 2011 12834 12841
78. J. Wang Exploring organosilane amines as potent inhibitors and structural probes of influenza A virus M2 proton channel J. Am. Chem. Soc. 133 2011 13844 13847
79. J. Hu Histidines, heart of the hydrogen ion channel from influenza A virus: toward an understanding of conductance and proton selectivity Proc. Natl Acad. Sci. U. S. A. 103 2006 6865 6870
80. P. Venkataraman Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza A virus J. Biol. Chem. 280 2005 21463 21472
81. Y. Tang The gate of the influenza virus M2 proton channel is formed by a single tryptophan residue J. Biol. Chem. 277 2002 39880 39886
82. A. Portela, and P. Digard The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication J. Gen. Virol. 83 2002 723 734
83. Q. Ye The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA Nature 444 2006 1078 1082
84. A.K-L. Ng Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design FASEB J. 22 2008 3638 3647
85. R. Coloma The structure of a biologically active influenza virus ribonucleoprotein complex PLoS Pathog. 5 2009 e1000491
86. S. Boulo Nuclear traffic of influenza virus proteins and ribonucleoprotein complexes Virus Res. 124 2007 12 21
87. R.Y. Kao Identification of influenza A nucleoprotein as an antiviral target Nat. Biotechnol. 28 2010 600 605
88. S.W. Gerritz Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers Proc. Natl Acad. Sci. U. S. A. 108 2011 15366 15371
89. C-Y. Su High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity Proc. Natl Acad. Sci. U. S. A. 107 2010 19151 19156
90. W.H. Chan Functional analysis of the influenza virus H5N1 nucleoprotein tail loop reveals amino acids that are crucial for oligomerization and ribonucleoprotein activities J. Virol. 84 2010 7337 7345
91. Y-F. Shen E339...R416 salt bridge of nucleoprotein as a feasible target for influenza virus inhibitors Proc. Natl Acad. Sci. U. S. A. 108 2011 16515 16520
92. P. Fedichev Structure-based drug design of a new chemical class of small molecules active against influenza A nucleoprotein in vitro and in vivo PLoS Curr. 2011 RRN1253
93. R.M. Krug Are the 5' ends of influenza viral mRNAs synthesized in vivo donated by host mRNAs? Cell 18 1979 329 334
94. C. Zhao Nucleoside monophosphate complex structures of the endonuclease domain from the influenza virus polymerase PA subunit reveal the substrate binding site inside the catalytic center J. Virol. 83 2009 9024 9030
95. X. He Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus Nature 454 2008 1123 1126
96. E. Obayashi The structural basis for an essential subunit interaction in influenza virus RNA polymerase Nature 454 2008 1127 1131
97. K. Sugiyama Structural insight into the essential PB1-PB2 subunit contact of the influenza virus RNA polymerase EMBO J. 28 2009 1803 1811
98. D. Guilligay The structural basis for cap binding by influenza virus polymerase subunit PB2 Nat. Struct. Mol. Biol. 15 2008 500 506
99. T. Kuzuhara Structural basis of the influenza A virus RNA polymerase PB2 RNA-binding domain containing the pathogenicity-determinant lysine 627 residue J. Biol. Chem. 284 2009 6855 6860
100. F. Tarendeau Structure and nuclear import function of the C-terminal domain of influenza virus polymerase PB2 subunit Nat. Struct. Mol. Biol. 14 2007 229 233
101. Y. Iwai Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts PLoS One 6 2011 e19825
102. A. Ghanem Peptide-mediated interference with influenza A virus polymerase J. Virol. 81 2007 7801 7804
103. K. Martin, and A. Heleniust Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import Cell 67 1991 117 130
104. P. Gómez-Puertas Influenza virus matrix protein is the major driving force in virus budding J. Virol. 74 2000 11538 11547
105. B. Sha, and M. Luo Structure of a bifunctional membrane-RNA binding protein, influenza virus matrix protein M1 Nat. Struct. Biol. 4 1997 239 244
106. S. Arzt Combined results from solution studies on intact influenza virus M1 protein and from a new crystal form of its N-terminal domain show that M1 is an elongated monomer Virology 279 2001 439 446
107. T. Liu, and Z. Ye Restriction of viral replication by mutation of the influenza virus matrix protein J. Virol. 76 2002 13055 13061
108. H. Akarsu Crystal structure of the M1 protein-binding domain of the influenza A virus nuclear export protein (NEP/NS2) EMBO J. 22 2003 4646 4655
109. B.G. Hale The multifunctional NS1 protein of influenza A viruses J. Gen. Virol. 89 2008 2359 2376
110. A. Cheng Structural basis for dsRNA recognition by NS1 protein of influenza A virus Cell Res. 19 2009 187 195
111. K. Das Structural basis for suppression of a host antiviral response by influenza A virus Proc. Natl Acad. Sci. U. S. A. 105 2008 13093 13098
112. K.Y. Twu The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target J. Virol. 80 2006 3957 3965
113. D. Basu Novel influenza virus NS1 antagonists block replication and restore innate immune function J. Virol. 83 2009 1881 1891
114. J. Talon Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach Proc. Natl Acad. Sci. U. S. A. 97 2000 4309 4314
115. H. Akarsu Structure-based design of NS2 mutants for attenuated influenza A virus vaccines Virus Res. 155 2011 240 248
116. J.L. McKimm-Breschkin Resistance of influenza viruses to neuraminidase inhibitors - a review Antiviral. Res. 47 2000 1 17